Abstract 768: A kinome-wide siRNA screen identifies modifiers of sensitivity to the EGFR T790M-targeted tyrosine kinase inhibitor (TKI), AZD9291, in EGFR mutant lung adenocarcinoma

Kinase Inhibitor ◽

Sirna Screen ◽

Egfr Mutant ◽

Egfr T790m

Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival

Pathology - Research and Practice ◽

10.1016/j.prp.2018.01.010 ◽

2018 ◽

Vol 214 (3) ◽

pp. 335-342 ◽

Cited By ~ 4

Author(s):

Soon Auck Hong ◽

Si-Hyong Jang ◽

Mee-Hye Oh ◽

Sung Joon Kim ◽

Jin-Hyung Kang ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Poor Survival ◽

Tyrosine Kinase Inhibitor Therapy ◽

Abstract 2609: Overexpression of YAP1 of EGFR-mutant lung adenocarcinoma before tyrosine kinase inhibitor is associated with poor survival

10.1158/1538-7445.am2018-2609 ◽

2018 ◽

Author(s):

Soon Auck Hong ◽

Jin-Hyoung Kang ◽

Sook Hee Hong

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Poor Survival ◽

Uncovering tyrosine kinase inhibitor resistance mutations in EGFR mutant lung adenocarcinoma using whole-exome sequencing

10.5353/th_991044168862503414 ◽

2019 ◽

Author(s):

Xuyuan Gao

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Exome Sequencing ◽

Whole Exome Sequencing ◽

Kinase Inhibitor ◽

Resistance Mutations ◽

Whole Exome ◽

Egfr Mutant ◽

Inhibitor Resistance

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

OncoTargets and Therapy ◽

10.2147/ott.s62639 ◽

2014 ◽

pp. 799 ◽

Cited By ~ 9

Author(s):

Jeng-Sen Tseng ◽

Tsung-Ying Yang ◽

Kun-Chieh Chen ◽

Kuo-Hsuan Hsu ◽

Chong-Jen Yu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy ◽

Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report

Oncology Letters ◽

10.3892/ol.2017.6913 ◽

2017 ◽

Cited By ~ 1

Author(s):

Rossella Bruno ◽

Agnese Proietti ◽

Greta Alï¿½ ◽

Gianfranco Puppo ◽

Alessandro Ribechini ◽

...

Keyword(s):

Case Report ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Cell Transformation ◽

Acquired Resistance ◽

Resistance Mechanisms ◽

T790m Mutation ◽

Egfr T790m

Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation

Cancer Biology & Therapy ◽

10.1080/15384047.2020.1776579 ◽

2020 ◽

Vol 21 (8) ◽

pp. 741-748

Author(s):

Sang Hoon Lee ◽

Eun Young Kim ◽

Arum Kim ◽

Yoon Soo Chang

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Clinical Implication ◽

Kinase Inhibitor ◽

De Novo ◽

T790m Mutation ◽

Egfr Tyrosine Kinase ◽

Egfr T790m

Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-021-03731-2 ◽

2021 ◽

Author(s):

Yu-Jin Wang ◽

Qing-Wen Wang ◽

Dong-Hu Yu ◽

Cong-Kuan Song ◽

Zi-Xin Guo ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Epidermal Growth

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1514 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2230

Author(s):

R. Rosell ◽

N. Karachaliou ◽

J.J. Cui ◽

I. Chaib ◽

J. Berenguer ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Innate Resistance ◽

Egfr Tyrosine Kinase ◽

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma

JCI Insight ◽

10.1172/jci.insight.125693 ◽

2019 ◽

Vol 4 (4) ◽

Cited By ~ 13

Author(s):

Rita Tohmé ◽

Sudeh Izadmehr ◽

Sai Gandhe ◽

Giancarlo Tabaro ◽

Sanjay Vallabhaneni ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Direct Activation